New Zealand-based investment firm Movac was quick to sell a portion of its shares in Aroa Biosurgery as soon as it could after the biotech company's ASX-listing in June.
The Movac Fund 3 and Movac Sidecar 3 Fund sold millions of shares in Aroa - shrinking the firm's stake in the soft tissue
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
